Rhenman & Partners Asset Management Ab Biomarin Pharmaceutical Inc Transaction History
Rhenman & Partners Asset Management Ab
- $840 Million
- Q1 2025
A detailed history of Rhenman & Partners Asset Management Ab transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 265,000 shares of BMRN stock, worth $14.6 Million. This represents 2.23% of its overall portfolio holdings.
Number of Shares
265,000
Previous 250,623
5.74%
Holding current value
$14.6 Million
Previous $16.5 Million
13.71%
% of portfolio
2.23%
Previous 1.72%
Shares
30 transactions
Others Institutions Holding BMRN
# of Institutions
668Shares Held
184MCall Options Held
1.24MPut Options Held
957K-
Black Rock Inc. New York, NY22.7MShares$1.25 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$1.05 Billion0.03% of portfolio
-
Primecap Management CO Pasadena, CA17.8MShares$978 Million1.06% of portfolio
-
Dodge & Cox San Francisco, CA15MShares$823 Million0.65% of portfolio
-
Viking Global Investors LP10.8MShares$594 Million2.55% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $10.2B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...